Biofrontera Inc. completes final patient visit in Phase 2b clinical trial for acne vulgaris treatment, with top-line results expected in Q1 2026. The company plans to discuss results with the FDA in Q3 2026 for potential label expansion. Acne affects over 50 million people in the US annually, with the market valued at $5.7 billion in 2024. The trial utilized red-light Photodynamic Therapy (PDT) with Ameluz® to address the significant unmet need for alternative treatment options for moderate to severe acne vulgaris. If successful, Ameluz® could offer a new, effective treatment option for patients.

Read more at GlobeNewswire: Biofrontera Inc. Announces Last-Patient-Out in Phase 2b